Squamous Cell Carcinoma of Head and Neck: all 1,711 studies

Page 15 of 18. Open to participants first (544), then studies with results posted, then the rest; newest registration first within each.

• A Dye for the Detection of Cancer of the Tongue and MouthActive, not recruitingNCT03085147Phase 1/2
• A Study Evaluating MM-310 in Patients With Solid TumorsStatus unknownNCT03076372Phase 1
• CTC Detection Rate in SCCHN With a in Vivo DeviceStatus unknownNCT03071900Not applicable
• Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCCActive, not recruitingNCT03070366Phase 2
• Immune Response Evaluation to Curative Conventional TherapyStatus unknownNCT03053661
• WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck CancerCompletedNCT03028766Phase 1
• Molecular Mechanisms of the Development of Precancerous and Cancerous Lesions of the Oral CavityCompletedNCT03026361
• A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).CompletedNCT03022409Phase 1
• Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCCCompletedNCT02999646Not applicable
• Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)Active, not recruitingNCT02999087Phase 3
• Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral CavityWithdrawnNCT02993991Phase 1
• A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsActive, not recruitingNCT02988960Phase 1
• Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal CarcinomaActive, not recruitingNCT02984410Not applicable
• Post-marketing Surveillance Study of Docetaxel-Based ChemotherapyCompletedNCT02972216
• CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerActive, not recruitingNCT02955290Phase 1/2
• A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsTerminatedNCT02952989Phase 1
• Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)CompletedNCT02938273Phase 1
• Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity CancerCompletedNCT02923258Phase 2/3
• The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Phase 1/2
• A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck CancerTerminatedNCT02901483Phase 1/2
• Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.CompletedNCT02882308Phase 2
• Anti-tumor Specific Immune Response in Head and Neck CancersStatus unknownNCT02881918
• Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot StudyCompletedNCT02862678Not applicable
• One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell CarcinomaCompletedNCT02852343
• Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN LossTerminatedNCT02822482Phase 1/2
• Ipilimumab for Head and Neck Cancer PatientsActive, not recruitingNCT02812524Phase 1
• Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck CancerCompletedNCT02794675Early Phase 1
• Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell CarcinomaCompletedNCT02778191
• Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and NeckCompletedNCT02776137Phase 2
• Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell CarcinomaCompletedNCT02775812Phase 1
• Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT02769520Phase 2
• Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO TrialStatus unknownNCT02765503Not applicable
• Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck CancerCompletedNCT02764593Phase 1
• Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant ChemotherapyStatus unknownNCT02753140Phase 2
• TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility StudyCompletedNCT02752932Not applicable
• Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized StudyStatus unknownNCT02748707Phase 2
• Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell CarcinomaStatus unknownNCT02739204Phase 2
• Changes in Body Composition After EPA Supplementation in Head and Neck PatientsCompletedNCT02715596Phase 3
• Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCCCompletedNCT02707588Phase 2
• Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCCWithdrawnNCT02686008Phase 1
• Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot StudyCompletedNCT02678884Not applicable
• DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.Status unknownNCT02661152Phase 3
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1
• Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck CancerTerminatedNCT02655068Phase 3
• A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell CarcinomaWithdrawnNCT02649530Phase 2
• Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02643550Phase 1/2
• Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCCStatus unknownNCT02639858Phase 2
• Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial TumorsCompletedNCT02636036Phase 1
• E10A for the Treatment of Squamous Cell Carcinoma of the Head and NeckStatus unknownNCT02630264Phase 3
• Safety Study of MGD009 in B7-H3-expressing TumorsTerminatedNCT02628535Phase 1
• Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and NeckStatus unknownNCT02624128Phase 2
• Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic AcidCompletedNCT02608736Early Phase 1
• Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck CancerWithdrawnNCT02593929Early Phase 1
• Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCCCompletedNCT02585973Phase 1
• Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyTerminatedNCT02582008Early Phase 1
• GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsCompletedNCT02575404Phase 1
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid TumorsCompletedNCT02565758Phase 1
• PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCCCompletedNCT02544880Phase 1
• SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)CompletedNCT02543476
• AMG 319 in HPV Positive and Negative HNSCCTerminatedNCT02540928Phase 2
• Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibTerminatedNCT02538627Phase 1
• Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck CancerCompletedNCT02537223Phase 1
• Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During ChemoradiationCompletedNCT02531906Phase 1
• Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard InjectionCompletedNCT02510872Not applicable
• Nutrition and Life QUality Patients With Head and Neck CancersCompletedNCT02510859Not applicable
• WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and NeckCompletedNCT02508246Phase 1
• Reactivating NK Cells in Treating Refractory Head and Neck CancerStatus unknownNCT02507154Phase 1/2
• Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasActive, not recruitingNCT02503423Phase 1/2
• Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT02495896Phase 1
• Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' PatientsStatus unknownNCT02495064Phase 4
• A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02479178Phase 2
• A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer PatientsCompletedNCT02473731Phase 1
• HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal CancerTerminatedNCT02464137Phase 1
• Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or SkinTerminatedNCT02449681Phase 2
• Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02438995Phase 1
• Safety Study of AMG 228 to Treat Solid TumorsTerminatedNCT02437916Phase 1
• The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck CancersCompletedNCT02435602Not applicable
• Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyActive, not recruitingNCT02432963Phase 1
• Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and NeckTerminatedNCT02429089Phase 1
• Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and CisplatinCompletedNCT02381535Phase 1
• Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
• A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorTerminatedNCT02365662Phase 1
• Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck CancerStatus unknownNCT02352792Not applicable
• Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck CancerCompletedNCT02350712Phase 1
• A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid TumorsCompletedNCT02335918Phase 1/2
• Ganetespib Window of Opportunity Study in Head and Neck CancersTerminatedNCT02334319Phase 1
• Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung CancerCompletedNCT02318771Phase 1
• Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck CancerCompletedNCT02308072Phase 1
• Fluorescent Visualization in Early Oral CancerCompletedNCT02306967Not applicable
• Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell CarcinomaWithdrawnNCT02298595Phase 1/2
• Dual-Energy CT in Patients With Head and Neck Squamous Cell CarcinomasCompletedNCT02279459
• Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT02277197Phase 1
• Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT02277184Phase 1
• Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT02270814Phase 2
• Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCCCompletedNCT02268695Phase 2
• A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerCompletedNCT02262741Phase 1
• Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or EsophagusTerminatedNCT02254044Phase 1
• Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT02254018Phase 1
• Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung CancerCompletedNCT02245100

← Squamous Cell Carcinoma of Head and Neck overview